Brokerages Set LB Pharmaceuticals Inc (NASDAQ:LBRX) PT at $49.62

Posted by Geri Gentry on Sep 7th, 2026

Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $49.6250.

LBRX has been the topic of several analyst reports. Roth Capital reissued a “buy” rating and issued a $37.00 target price on shares of LB Pharmaceuticals in a research note on Sunday, May 17th. BMO Capital Markets increased their price objective on shares of LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Stifel Nicolaus set a $53.00 price objective on shares of LB Pharmaceuticals in a report on Thursday, August 13th. Wolfe Research assumed coverage on shares of LB Pharmaceuticals in a research report on Tuesday, July 7th. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, HC Wainwright upped their target price on shares of LB Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, August 24th.

Read Our Latest Research Report on LBRX

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LBRX. California State Teachers Retirement System bought a new stake in LB Pharmaceuticals in the 4th quarter valued at approximately $26,000. Bank of America Corp DE bought a new position in shares of LB Pharmaceuticals during the 3rd quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new position in shares of LB Pharmaceuticals during the 4th quarter worth approximately $34,000. Strs Ohio acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter valued at approximately $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter valued at approximately $91,000.

LB Pharmaceuticals Price Performance

LB Pharmaceuticals stock opened at $49.34 on Monday. The business’s 50-day simple moving average is $40.54 and its 200 day simple moving average is $32.08. The stock has a market cap of $1.59 billion and a price-to-earnings ratio of -14.34. LB Pharmaceuticals has a 12-month low of $13.36 and a 12-month high of $50.16.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.87). As a group, sell-side analysts expect that LB Pharmaceuticals will post -5.16 EPS for the current year.

About LB Pharmaceuticals

(Get Free Report)

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.